
Plasma Derived Medicine Industry Research Report 2025
Description
Summary
According to APO Research, The global Plasma Derived Medicine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Plasma Derived Medicine include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Plasma Derived Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasma Derived Medicine.
The Plasma Derived Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Plasma Derived Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Plasma Derived Medicine Segment by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Plasma Derived Medicine Segment by Type
Albumin
Immune Globulin
Coagulation Factor
Others
Plasma Derived Medicine Segment by Application
Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Application
Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Plasma Derived Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Plasma Derived Medicine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Plasma Derived Medicine include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Plasma Derived Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasma Derived Medicine.
The Plasma Derived Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Plasma Derived Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Plasma Derived Medicine Segment by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Plasma Derived Medicine Segment by Type
Albumin
Immune Globulin
Coagulation Factor
Others
Plasma Derived Medicine Segment by Application
Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Application
Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Plasma Derived Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
133 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Plasma Derived Medicine by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Albumin
- 2.2.3 Immune Globulin
- 2.2.4 Coagulation Factor
- 2.2.5 Others
- 2.3 Plasma Derived Medicine by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
- 3 Plasma Derived Medicine Breakdown Data by Type
- 3.1 Global Plasma Derived Medicine Historic Market Size by Type (2020-2025)
- 3.2 Global Plasma Derived Medicine Forecasted Market Size by Type (2026-2031)
- 4 Plasma Derived Medicine Breakdown Data by Application
- 4.1 Global Plasma Derived Medicine Historic Market Size by Application (2020-2025)
- 4.2 Global Plasma Derived Medicine Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Plasma Derived Medicine Market Perspective (2020-2031)
- 5.2 Global Plasma Derived Medicine Growth Trends by Region
- 5.2.1 Global Plasma Derived Medicine Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Plasma Derived Medicine Historic Market Size by Region (2020-2025)
- 5.2.3 Plasma Derived Medicine Forecasted Market Size by Region (2026-2031)
- 5.3 Plasma Derived Medicine Market Dynamics
- 5.3.1 Plasma Derived Medicine Industry Trends
- 5.3.2 Plasma Derived Medicine Market Drivers
- 5.3.3 Plasma Derived Medicine Market Challenges
- 5.3.4 Plasma Derived Medicine Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Plasma Derived Medicine Players by Revenue
- 6.1.1 Global Top Plasma Derived Medicine Players by Revenue (2020-2025)
- 6.1.2 Global Plasma Derived Medicine Revenue Market Share by Players (2020-2025)
- 6.2 Global Plasma Derived Medicine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Plasma Derived Medicine Head Office and Area Served
- 6.4 Global Plasma Derived Medicine Players, Product Type & Application
- 6.5 Global Plasma Derived Medicine Manufacturers Established Date
- 6.6 Global Plasma Derived Medicine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Plasma Derived Medicine Market Size (2020-2031)
- 7.2 North America Plasma Derived Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Plasma Derived Medicine Market Size by Country (2020-2025)
- 7.4 North America Plasma Derived Medicine Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Plasma Derived Medicine Market Size (2020-2031)
- 8.2 Europe Plasma Derived Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Plasma Derived Medicine Market Size by Country (2020-2025)
- 8.4 Europe Plasma Derived Medicine Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Plasma Derived Medicine Market Size (2020-2031)
- 9.2 Asia-Pacific Plasma Derived Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Plasma Derived Medicine Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Plasma Derived Medicine Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Plasma Derived Medicine Market Size (2020-2031)
- 10.2 South America Plasma Derived Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Plasma Derived Medicine Market Size by Country (2020-2025)
- 10.4 South America Plasma Derived Medicine Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Plasma Derived Medicine Market Size (2020-2031)
- 11.2 Middle East & Africa Plasma Derived Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Plasma Derived Medicine Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Plasma Derived Medicine Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Yuanda Shuyang
- 12.1.1 Yuanda Shuyang Company Information
- 12.1.2 Yuanda Shuyang Business Overview
- 12.1.3 Yuanda Shuyang Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.1.4 Yuanda Shuyang Plasma Derived Medicine Product Portfolio
- 12.1.5 Yuanda Shuyang Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.2.4 Takeda Plasma Derived Medicine Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Weiguang Bio
- 12.3.1 Weiguang Bio Company Information
- 12.3.2 Weiguang Bio Business Overview
- 12.3.3 Weiguang Bio Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.3.4 Weiguang Bio Plasma Derived Medicine Product Portfolio
- 12.3.5 Weiguang Bio Recent Developments
- 12.4 Tiantan Bio
- 12.4.1 Tiantan Bio Company Information
- 12.4.2 Tiantan Bio Business Overview
- 12.4.3 Tiantan Bio Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.4.4 Tiantan Bio Plasma Derived Medicine Product Portfolio
- 12.4.5 Tiantan Bio Recent Developments
- 12.5 CBPO
- 12.5.1 CBPO Company Information
- 12.5.2 CBPO Business Overview
- 12.5.3 CBPO Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.5.4 CBPO Plasma Derived Medicine Product Portfolio
- 12.5.5 CBPO Recent Developments
- 12.6 Shuanglin Bio
- 12.6.1 Shuanglin Bio Company Information
- 12.6.2 Shuanglin Bio Business Overview
- 12.6.3 Shuanglin Bio Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.6.4 Shuanglin Bio Plasma Derived Medicine Product Portfolio
- 12.6.5 Shuanglin Bio Recent Developments
- 12.7 RAAS
- 12.7.1 RAAS Company Information
- 12.7.2 RAAS Business Overview
- 12.7.3 RAAS Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.7.4 RAAS Plasma Derived Medicine Product Portfolio
- 12.7.5 RAAS Recent Developments
- 12.8 Nanyue Bio
- 12.8.1 Nanyue Bio Company Information
- 12.8.2 Nanyue Bio Business Overview
- 12.8.3 Nanyue Bio Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.8.4 Nanyue Bio Plasma Derived Medicine Product Portfolio
- 12.8.5 Nanyue Bio Recent Developments
- 12.9 Hualan Bio
- 12.9.1 Hualan Bio Company Information
- 12.9.2 Hualan Bio Business Overview
- 12.9.3 Hualan Bio Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.9.4 Hualan Bio Plasma Derived Medicine Product Portfolio
- 12.9.5 Hualan Bio Recent Developments
- 12.10 Boya Bio
- 12.10.1 Boya Bio Company Information
- 12.10.2 Boya Bio Business Overview
- 12.10.3 Boya Bio Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.10.4 Boya Bio Plasma Derived Medicine Product Portfolio
- 12.10.5 Boya Bio Recent Developments
- 12.11 Octapharma
- 12.11.1 Octapharma Company Information
- 12.11.2 Octapharma Business Overview
- 12.11.3 Octapharma Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.11.4 Octapharma Plasma Derived Medicine Product Portfolio
- 12.11.5 Octapharma Recent Developments
- 12.12 LFB Group
- 12.12.1 LFB Group Company Information
- 12.12.2 LFB Group Business Overview
- 12.12.3 LFB Group Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.12.4 LFB Group Plasma Derived Medicine Product Portfolio
- 12.12.5 LFB Group Recent Developments
- 12.13 KM Biologics
- 12.13.1 KM Biologics Company Information
- 12.13.2 KM Biologics Business Overview
- 12.13.3 KM Biologics Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.13.4 KM Biologics Plasma Derived Medicine Product Portfolio
- 12.13.5 KM Biologics Recent Developments
- 12.14 Kedrion
- 12.14.1 Kedrion Company Information
- 12.14.2 Kedrion Business Overview
- 12.14.3 Kedrion Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.14.4 Kedrion Plasma Derived Medicine Product Portfolio
- 12.14.5 Kedrion Recent Developments
- 12.15 Grifols
- 12.15.1 Grifols Company Information
- 12.15.2 Grifols Business Overview
- 12.15.3 Grifols Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.15.4 Grifols Plasma Derived Medicine Product Portfolio
- 12.15.5 Grifols Recent Developments
- 12.16 CSL
- 12.16.1 CSL Company Information
- 12.16.2 CSL Business Overview
- 12.16.3 CSL Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.16.4 CSL Plasma Derived Medicine Product Portfolio
- 12.16.5 CSL Recent Developments
- 12.17 BPL
- 12.17.1 BPL Company Information
- 12.17.2 BPL Business Overview
- 12.17.3 BPL Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.17.4 BPL Plasma Derived Medicine Product Portfolio
- 12.17.5 BPL Recent Developments
- 12.18 Biotest
- 12.18.1 Biotest Company Information
- 12.18.2 Biotest Business Overview
- 12.18.3 Biotest Revenue in Plasma Derived Medicine Business (2020-2025)
- 12.18.4 Biotest Plasma Derived Medicine Product Portfolio
- 12.18.5 Biotest Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.